tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Spinal Cord Injuries D013119 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Burns D002056 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Memory Disorders D008569 33 associated lipids
Uremia D014511 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Stratta RJ et al. Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation? 2004 Transplant. Proc. pmid:15194373
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Neylan JF Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636551
Diez Ojea B et al. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. 2009 Jul-Aug Transplant. Proc. pmid:19715908
Gallego-Valcarce E et al. Conversion to tacrolimus extended-release formulation: short-term clinical results. 2009 Jul-Aug Transplant. Proc. pmid:19715909
Corry RJ et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. 1998 Transplant. Proc. pmid:9532157
Dheir H et al. Intensive polyoma virus nephropathy treatment as a preferable approach for graft surveillance. 2011 Transplant. Proc. pmid:21486617
Waller JR et al. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. 2005 Jan-Feb Transplant. Proc. pmid:15808582
Cimsit B et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. 2011 Transplant. Proc. pmid:21486625
Zhao Y et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808586
Shimada H et al. Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression. 2000 Transplant. Proc. pmid:11119931
Vela CG et al. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients. 2000 Transplant. Proc. pmid:10715453
Kim HC and Park SB Mycophenolate mofetil-induced ischemic colitis. 2000 Transplant. Proc. pmid:11119990
Stephens J et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. 1993 Transplant. Proc. pmid:7680144
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Pan F et al. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. 1996 Transplant. Proc. pmid:8623373
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Tian JH et al. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. 2009 Transplant. Proc. pmid:19917365
Díaz-Molina B et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. 2012 Transplant. Proc. pmid:23146479
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
San Segundo D et al. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. 2012 Transplant. Proc. pmid:23146491
Tanabe K et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. 2004 Transplant. Proc. pmid:15518791
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Ishibashi M et al. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. 1999 Transplant. Proc. pmid:10578281
Tojimbara T et al. Oral vs intravenous tacrolimus-based induction therapy in renal transplantation. 1999 Transplant. Proc. pmid:10578282
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Nakamura Y et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. 2005 Transplant. Proc. pmid:15919445
Furukawa H and Todo S Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. 2004 Transplant. Proc. pmid:15041353
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Sano N et al. Oral FK 506 blood levels are elevated in pig short bowel model: further investigations with co-administration of an intestinal CYP3A4 inhibitor. 2002 Transplant. Proc. pmid:12034301
Aguirrezabalaga J et al. Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin. 2002 Transplant. Proc. pmid:12176480
Dierickx D et al. Thrombotic microangiopathy following intestinal transplantation: a single center experience. 2010 Jan-Feb Transplant. Proc. pmid:20172285
de Oliveira Clark RM et al. Evaluation of hemodynamic, metabolic, and electrolytic changes after graft reperfusion in a porcine model of intestinal transplantation. 2010 Jan-Feb Transplant. Proc. pmid:20172287
Gerauer K et al. Long-term cardiac allograft survival in mice treated with malononitrilamide 715. 1998 Transplant. Proc. pmid:9865349
Prasad GV et al. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919496
Hohage H et al. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study. 2005 Transplant. Proc. pmid:15919497
Jordan ML et al. Five-year experience with tacrolimus rescue for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123009
Yamada T et al. Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8907927
Malaise J et al. Tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: the EURO-SPK 3-year results. 2005 Jul-Aug Transplant. Proc. pmid:16182828
Malaise J et al. Corticosteroid withdrawal in simultaneous pancreas-kidney transplantation: a 3-year report. 2005 Jul-Aug Transplant. Proc. pmid:16182832
Nakata S et al. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes. 1994 Transplant. Proc. pmid:7520613
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Crespo-Leiro MG Tacrolimus in heart transplantation. 2003 Transplant. Proc. pmid:12962869
Espí A et al. Influence of hepatic ischemia-reperfusion injury on tacrolimus acute renal toxicity in pigs. 2002 Transplant. Proc. pmid:12493373
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Aumente Rubio MD et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. 2003 Transplant. Proc. pmid:12962871
Soylu H et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. 2015 Transplant. Proc. pmid:25769571
Dietl KH Oral dosing of tacrolimus and cyclosporine microemulsion--results from a large multicenter study in renal transplantation. 2002 Transplant. Proc. pmid:12176524
Karakulska-Prystupiuk E et al. Pericarditis in Patients With Chronic Graft-vs-Host Disease. 2018 Transplant. Proc. pmid:30177139
Gurkan A et al. Comparison of tacrolimus and neoral-based immunosuppressive regimens in renal transplantation patients: singles-center experience. 2002 Transplant. Proc. pmid:12176525
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Kumano K et al. Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. 1997 Feb-Mar Transplant. Proc. pmid:9123293
Hatakeyama S et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310594
Grochowicz PM et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. 1997 Feb-Mar Transplant. Proc. pmid:9123296
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Mori T et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. 2007 Transplant. Proc. pmid:17580201
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Baran DA et al. A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. 2002 Transplant. Proc. pmid:12176595
Nakatani T et al. Effect of tacrolimus on the gene expression of renin and endothelin in the rat kidney. 2001 Transplant. Proc. pmid:11377534
Ettenger R The practical problems of prednisone in pediatric renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267159
Sánchez Pérez B et al. Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels. 2009 Transplant. Proc. pmid:19376418
Reggiani P et al. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. 1998 Transplant. Proc. pmid:9723308
Testillano M et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. 2009 Transplant. Proc. pmid:19376421
Alberti D et al. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723310
Jiménez-Pérez M et al. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation. Transplant. Proc. pmid:25645779
Kishikawa H et al. Low-dose steroid maintenance for renal transplant recipients. 2010 Transplant. Proc. pmid:21168618
Tinti F et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. 2010 Transplant. Proc. pmid:21168623
Shaffer D et al. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications. 2006 Transplant. Proc. pmid:17175304
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
Todo S et al. Orthotopic liver transplantation in dogs receiving FK-506. 1987 Transplant. Proc. pmid:2445079
Lim SM et al. Heterotopic heart transplantation in the rat receiving FK-506. 1987 Transplant. Proc. pmid:2445080
Mohamed MA et al. TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267336
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients. 1999 Transplant. Proc. pmid:10500604
Abou-Jaoude MM et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. 2005 Transplant. Proc. pmid:16213293
Kanbay M et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. 2005 Transplant. Proc. pmid:16213325
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Braun F et al. Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. 1998 Transplant. Proc. pmid:9636496
Tanabe K et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. 1998 Transplant. Proc. pmid:9636497
Tamura S et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A single-center experience at the University of Tokyo. 2004 Transplant. Proc. pmid:15686738
Szabó L et al. Effect of tacrolimus on the excitatory synaptic transmission between the parallel fibers and pyramidal cells in the rat dorsal cochlear nucleus. 2010 Jul-Aug Transplant. Proc. pmid:20692476
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823